|
|
Utilization of narrow-band ultraviolet light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
- From:
- Journal of Drugs in Dermatology
- Date:
- March 1, 2008
- Author:
- Bagel, Jerry; Chiou, Chiun-Fang; Dann, Frank; Elmets, Craig A.; Kircik, Leon; Koo, John; Korman, Neil; Menter, Alan; Stevens, Seth R.; Yang, Yu-Ching
|
Copyright information
COPYRIGHT 2008 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
|
Background: Moderate to severe psoriasis is a significant inflammatory disease that frequently requires systemic therapies to effectively treat the underlying disorder. Etanercept and narrow-band ultraviolet light B (NB-UVB) are widely used to treat this disease.
Objective: To evaluate the effectiveness, tolerability, and patient-reported outcomes of combination etanercept plus NB-UVB phototherapy in moderate to severe plaque psoriasis.
Methods: This 12-week, single-arm, open-label study evaluated the combination of etanercept 50 mg twice weekly and NB-UVB thrice weekly in 86 patients. The primary outcome measure was [greater than or equal to] 75% improvement from baseline in the ...